The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The China genetic testing market reached a value of US$ 2.76 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 16.8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Genetic testing, also known as DNA testing, provides the determination of bloodlines and the genetic diagnosis of vulnerabilities to diseases that can be inherited. It determines changes in chromosomes, genes, or proteins. The results obtained from a genetic test can confirm or rule out a suspected genetic disorder or help identify a person’s chance of developing or passing on a genetic disorder. Genetic testing is becoming popular in China. It may benefit many different interest groups, such as individuals and families with a history of genetic disorder, pregnant women, employers, and health or life insurance. This market is currently driven by a number of factors such as rising awareness regarding the benefits of genetic testing, availability of direct to consumer tests and increasing incidences of genetic disorders.
Over the past few years, there has been a significant rise in the awareness levels regarding the benefits of genetic testing in China. Genetic testing provides various technologies that help in the early detection of various chronic diseases and ensures its treatment and prevention. Moreover, a rise in the availability of Direct to consumer tests (DTC) which has increased the convenience and accessibility of such tests is also creating a positive impact in the growth of the market. Moreover, In October, 2015, China announced that the iconic one-child policy had finally been replaced by a universal two-child policy. This is expected to increase the number of babies born each year and create a positive impact on the demand of the new born genetic testing segment. Other major factors that are expected to drive this market include growing middle class, aging population, and expanding healthcare system.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the China genetic testing market report, along with forecasts for growth at the country level from 2021-2026. Our report has categorized the market based on test type, disease, technology, service provider and testing sample.
Breakup by Test Type:
Based on the test type, the market has been divided as prenatal testing, newborn testing, diagnostic testing, carrier testing, predictive or presymptomatic testing and others. Amongst these, prenatal testing represents the biggest segment.
Breakup by Disease:
Based on the disease, the market has been segmented into cancer, down syndrome, thalassemia and others. Amongst these, cancer represents the biggest segment.
Breakup by Technology:
Based on the technology, the market has been segmented into cytogenetic, biochemical and molecular. Biochemical currently represents the biggest segment.
Breakup by Service Provider:
Based on the service provider, the market has been segmented into hospital based Laboratories, independent laboratories and specialty clinics. Amongst these, hospital based Laboratories has the largest share.
Breakup by Testing Sample:
Based on the testing samples, the market has been divided into blood, saliva, hair and others.
The report has also examined the competitive landscape of the China genetic testing market. Some of the major players include:
This report provides a deep insight into the China genetic testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the China genetic testing industry in any manner.
|Base Year of the Analysis||2020|
|Segment Coverage||Test Type, Disease, Technology, Service Provider, Testing Sample|
|Companies Covered||BGI, Berry Genomics Co. ltd., Daan Gene Co. Ltd, WuXi NextCODE, Annoroad Gene Technology Co. Ltd. and WuXi PharmaTech|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License $ 2499
Five User License $ 2999
Corporate License $ 3499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at